Good point on Nader, CJ. While I and many others question
Good point on Nader, CJ. While I and many others question some of his moves, decisions, public statements, etc., only a few seem to be bent on calling for his removal. That would be like changing managers in a pennant race in September. It would be great if message boards could demand or somehow provide transparency of paid posters to better assess the value of their contentions. Kinda like how the Cabinet appointees are supposed to be vetted for conflicts of interest, but rarely is, going way back. It's very healthy and provides badly needed perspective to discuss and evaluate the pros and cons of a key figure in a company we're invested in; it's unethical and borderline criminal to opine as a paid shill to defraud investors. Today's news shows he's got us on right track for approval, thru a phalanx of obstacles and opposition that few have dealt with. Good work, NP.
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...
Continue Reading
Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....
Continue Reading
Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...
Continue Reading
Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...
Continue Reading
Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...
Continue Reading
